[go: up one dir, main page]

WO2003015781A1 - Novel antidiabetic pharmaceutical compositions - Google Patents

Novel antidiabetic pharmaceutical compositions Download PDF

Info

Publication number
WO2003015781A1
WO2003015781A1 PCT/JP2002/008276 JP0208276W WO03015781A1 WO 2003015781 A1 WO2003015781 A1 WO 2003015781A1 JP 0208276 W JP0208276 W JP 0208276W WO 03015781 A1 WO03015781 A1 WO 03015781A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
pharmaceutical compositions
bonded
heteroaryl
novel antidiabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/008276
Other languages
French (fr)
Japanese (ja)
Inventor
Toshihiko Fujiwara
Shigeru Ushiyama
Tomio Kimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of WO2003015781A1 publication Critical patent/WO2003015781A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical compositions for the prevention or treatment of diabetes, containing as the active ingredient compounds represented by the general formula (I), or pharmacologically acceptable salts, esters, or other derivatives thereof: (I) wherein A is benzene, pyridine, pyridazine, pyrimidine, pyrrole, furan, thiophene, pyrazole, imidazole, isoxazole, or isothiazole, each being optionally substituted; R1 is aryl or heteroaryl, each being optionally substituted; R2 is optionally substituted nitrogenous heteroaryl; and R3 is a mono- or poly-cyclic nitrogenous heterocycle which may be substituted, with the proviso that the A-constituent atoms to which R1 and R3 bonded are each adjacent to the A-constituent atom to which R2 is bonded.
PCT/JP2002/008276 2001-08-15 2002-08-14 Novel antidiabetic pharmaceutical compositions Ceased WO2003015781A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001246344 2001-08-15
JP2001-246344 2001-08-15

Publications (1)

Publication Number Publication Date
WO2003015781A1 true WO2003015781A1 (en) 2003-02-27

Family

ID=19075908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008276 Ceased WO2003015781A1 (en) 2001-08-15 2002-08-14 Novel antidiabetic pharmaceutical compositions

Country Status (1)

Country Link
WO (1) WO2003015781A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009592A1 (en) * 2002-07-19 2004-01-29 Sankyo Company, Limited Bicyclic unsaturated tertiary amine compound
US7612094B2 (en) 2002-04-04 2009-11-03 Biogen Idec Ma Inc. Tri-substituted heteroaryls and methods of making and using the same
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2011042389A3 (en) * 2009-10-09 2012-08-16 Bayer Cropscience Ag Phenylpyri(mi)dinylazoles and their use as fungicides
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070711A2 (en) * 1999-07-21 2001-01-24 Sankyo Company Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
WO2002057264A1 (en) * 2001-01-22 2002-07-25 Sankyo Company Limited Pyrrole derivates for treating cytokine mediated diseases
WO2002057265A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited Compounds substituted with bicyclic amino groups
WO2002057255A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited 4- or 5-substituted pyrrole derivatives
JP2002284779A (en) * 2001-01-18 2002-10-03 Sankyo Co Ltd Medicine containing heteroaryl-substituted pyrrole derivative

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070711A2 (en) * 1999-07-21 2001-01-24 Sankyo Company Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
JP2002284779A (en) * 2001-01-18 2002-10-03 Sankyo Co Ltd Medicine containing heteroaryl-substituted pyrrole derivative
WO2002057264A1 (en) * 2001-01-22 2002-07-25 Sankyo Company Limited Pyrrole derivates for treating cytokine mediated diseases
WO2002057265A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited Compounds substituted with bicyclic amino groups
WO2002057255A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited 4- or 5-substituted pyrrole derivatives

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612094B2 (en) 2002-04-04 2009-11-03 Biogen Idec Ma Inc. Tri-substituted heteroaryls and methods of making and using the same
WO2004009592A1 (en) * 2002-07-19 2004-01-29 Sankyo Company, Limited Bicyclic unsaturated tertiary amine compound
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2011042389A3 (en) * 2009-10-09 2012-08-16 Bayer Cropscience Ag Phenylpyri(mi)dinylazoles and their use as fungicides
JP2013507334A (en) * 2009-10-09 2013-03-04 バイエル・クロップサイエンス・アーゲー Phenylpyri (mi) dinirazoles
EP2784071A1 (en) * 2009-10-09 2014-10-01 Bayer CropScience AG 3-phenyl-4-pyri(mi)dinyl-1h-pyrazoles and their use as fungicides
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same

Similar Documents

Publication Publication Date Title
WO2006070208A8 (en) Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists
IL164487A0 (en) 3-Heteroaryl substituted 5-methyloxymethyl isoxazolines used as herbicides
WO2007101060A3 (en) Compounds for the treatment of metabolic disorders
WO2005097129A3 (en) 6-azaindole compound
WO2007087505A3 (en) Compounds for the treatment of metabolic disorders
CA2424600A1 (en) Aliphatic nitrogenous five-membered ring compounds
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
EP1698628A4 (en) Hydroxypyrimidinone derivative having hiv integrase inhibitory activity
NO20081821L (en) Compounds for the treatment of metabolic disorders
WO2008111441A1 (en) Pharmaceutical composition
EP1702919A4 (en) NEW BENZIMIDAZOLE DERIVATIVE WITH 2-HETEROARYL SUBSTITUTION
WO2005000309A3 (en) Chemical compounds
NZ603896A (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
WO2004098496A3 (en) Compounds for the treatment of metabolic disorders
WO2004091486A3 (en) Compounds for the treatment of metabolic disorders
CA2336412A1 (en) Medicament for treatment of diabetes
CA2126465A1 (en) Inhibitor for restenosis after percutaneous coronary arterioplasty
WO2008153042A1 (en) Anti-tumor agent
WO2008056266A3 (en) Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a]pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[1,2-a]pyrimidin-6-one derivatives
WO2006127426A8 (en) Insecticidal substituted benzylamino heterocyclic and heteroaryl derivatives
WO2003015781A1 (en) Novel antidiabetic pharmaceutical compositions
CA2626767A1 (en) Heterocyclic substituted pyridine derivatives and antifungal agent containing same
WO2007093292A3 (en) Insecticidal substituted amino heterocyclic and heteroaryl derivatives
EP1361225A4 (en) Compounds substituted with bicyclic amino groups

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP